

## Special Issue

# Advances in Gene Therapy: Novel Vectors and Strategies

### Message from the Guest Editors

Gene therapy has the great potential to treat numerous diseases and has thus attracted attention from academia and industry in the past decade, evidenced by the performance of hundreds of on-going clinical trials and multiple high-profile regulatory approvals. In order to further enhance the safety and efficacy of gene therapies, extensive efforts have been made to formulate novel vectors and treatment strategies, ranging from viral capsid evolution, RNA editing, to on-target gene-editing strategies. This Special Issue welcomes the submission of review articles, short communications, or full-length research articles discussing novel methodologies, vector (non-viral and viral) development, and therapeutic approaches that have broad impacts in the field of gene therapy.

### Guest Editors

Dr. Li Ou

Dr. Michael Przybilla

Dr. Xin Chen

### Deadline for manuscript submissions

closed (25 February 2024)

G C A T  
T A C G  
G C A T

## Genes

---

an Open Access Journal  
by MDPI

---

**Impact Factor 2.8**  
**CiteScore 5.5**  
**Indexed in PubMed**



[mdpi.com/si/179697](https://mdpi.com/si/179697)

*Genes*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[genes@mdpi.com](mailto:genes@mdpi.com)

[mdpi.com/journal/  
genes](https://mdpi.com/journal/genes)



G C A T  
T A C G  
G C A T

# Genes

---

an Open Access Journal  
by MDPI

---

Impact Factor 2.8  
CiteScore 5.5  
Indexed in PubMed



[mdpi.com/journal/  
genes](https://mdpi.com/journal/genes)



## About the Journal

### Message from the Editor-in-Chief

*Genes* is central to our understanding of biology, and modern advances such as genomics and genome editing have maintained genetics as a vibrant, diverse and fast-moving field. There is a need for good quality, open access journals in this area, and the *Genes* team aims to provide expert manuscript handling, serious peer review, and rapid publication across the whole discipline of genetics. Starting in 2010, the journal is now well established and recognised. Why not consider *Genes* for your next genetics paper?

---

### Editor-in-Chief

Prof. Dr. Selvarangan Ponnazhagan  
Department of Pathology, The University of Alabama at Birmingham,  
1825 University Blvd, SHEL 814, Birmingham, AL 35294-2182, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

#### Journal Rank:

JCR - Q2 (Genetics and Heredity) / CiteScore - Q2 (Genetics (clinical))